CHMP recommends EU approval of Roche ’s Tecentriq in combination with Abraxane as an initial treatment for people with PD-L1-positive, metastatic triple-negative breast cancer

Roche today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) plus chemotherapy (Abraxane®; nab-paclitaxel) for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose t umours have PD-L1 expression (≥ 1%) and who have not received prior chemotherapy for metastatic disease.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news